Publications by authors named "Sever Ozlem"

Claim this Profile
T
Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage.
Tugba Basoglu, Ugur Ozkerim, Sila Oksuz, Oguzcan Kinikoglu, Sedat Yildirim, Ozlem Nuray Sever

J Clin Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC).
Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, Saadet Sim, Serhat Sekmek, Ozlem Nuray Sever

Clin Transl Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of smoking on nivolumab outcomes in renal cell carcinoma: real-world data from the Turkish Oncology Group Kidney Cancer Consortium.
Elif Sertesen Camoz, Hatice Bolek, Omer Faruk Kuzu, Saadet Sim, Hilal Karakaş, Ozlem Nuray Sever

Oncologist· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma.
Omer Faruk Kuzu, Hatice Bolek, Elif Sertesen Camoz, Hilal Karakas, Serhat Sekmek, Ozlem Nuray Sever

BMC Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study.
Serhat Sekmek, Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, Saadet Sim, Ozlem Nuray Sever

Immunotherapy· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium.
Hatice Bolek, Omer Faruk Kuzu, Elif Sertesen Camoz, Saadet Sim, Serhat Sekmek, Ozlem Nuray Sever

Cancer Commun (Lond)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis.
Sedat Yıldırım, Tugba Başoğlu, Akif Doğan, Goncagul Akdağ, Oguzcan Kınıkoğlu, Ozlem Nuray Sever

BMC Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium.
Musa Barış Aykan, Hatice Bölek, Emre Yekedüz, Elif Sertesen, Deniz Tural

Ther Adv Med Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.
Hatice Bölek, Elif Sertesen, Omer Faruk Kuzu, Deniz Tural, Saadet Sim

Clin Genitourin Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship of Tumor Localization and Lipid Parameters with Survival in Patients with Colorectal Cancer.
Özlem Nuray Sever, Tuğba Başoğlu, Sedat Yıldırım

J Clin Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study.
Akif Doğan, Nurullah İlhan, Goncagül Akdağ, Sedat Yıldırım, Mustafa Seyyar

Medicina (Kaunas)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older.
Deniz Isik, Özkan Alan, Goncagül Akdağ, Sedat Yildirim, Oğuzcan Kınıkoğlu, Ozlem Nuray Sever

J Clin Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2- Breast Cancer: Impact of Tumor Ki67 and ER Status.
Goncagul Akdag, Sedat Yildirim, Akif Dogan, Zeynep Yuksel Yasar, Hamit Bal, Ozlem Nuray Sever

Chemotherapy· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does Adjuvant Chemotherapy Benefit Patients with T4 N0 Colon Cancer?
Goncagul Akdag, Deniz Isik, Akif Dogan, Sedat Yildirim, Oguzcan Kinikoglu, Ozlem Nuray Sever

Medicina (Kaunas)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Impact and Clinical Features of Spread through Air Spaces in Operated Lung Cancer: Real-World Analysis.
Sedat Yildirim, Ozkan Alan, Zeynep Yuksel Yasar, Tugba Kaya, Goncagul Akdag, Ozlem Nuray Sever

Medicina (Kaunas)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients.
Sedat Yildirim, Akif Dogan, Goncagul Akdag, Eyyup Cavdar, Oguzcan Kinikoglu, Ozlem Nuray Sever

Cancers (Basel)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma.
Haci Arak, Suna Erkiliç, Şendağ Yaslikaya, Eda Eylemer Mocan, Gökmen Aktaş

J Immunother· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy.
Goncagul Akdag, Akif Dogan, Sedat Yildirim, Oguzcan Kinikoglu, Muhammed Edib Mokresh, Ozlem N Sever

Cureus· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy.
Sedat Yildirim, Akif Dogan, Goncagul Akdag, Zeynep Yüksel Yasar, Hamit Bal, Ozlem Nuray Sever

Sci Rep· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic scores in pulmonary large cell neuroendocrine carcinoma: A retrospective cohort study.
Goncagul Akdag, Özkan Alan, Akif Dogan, Sedat Yildirim, Oguzcan Kinikoglu, Ozlem Nuray Sever

Heliyon· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium.
Cihan Erol, Emre Yekedüz, Deniz Tural, Serdar Karakaya, Nihan Şentürk Öztaş

Urol Int· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.
Emre Yekedüz, Serdar Karakaya, İsmail Ertürk, Deniz Tural, Gökhan Uçar

Clin Genitourin Cancer· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study.
Emre Yekedüz, Deniz Tural, İsmail Ertürk, Serdar Karakaya, Cihan Erol

J Cancer Res Clin Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Ga-FAPI PET/CT and FDG PET/CT Modalities in Gastrointestinal System Malignancies with Peritoneal Involvement.
Umut Elboga, Ertan Sahin, Tulay Kus, Yusuf Burak Cayirli, Gokmen Aktas, Ozlem Nuray Sever

Mol Imaging Biol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors.
Kadriye Bir Yücel, Emre Yekedüz, Serdar Karakaya, Deniz Tural, İsmail Ertürk

Sci Rep· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis